Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

V Buxhofer-Ausch; A Reiter; C Tomuleasa; Albert Wölfler; L Teichmann; L Ocroteala; K Maria-Theresa; C Charu; S Schlager; V Empson; C Klade; K Krejcy; H Gisslinger; S Koschmieder

doi:10.1182/blood-2025-2032

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

V Buxhofer-Ausch
, A Reiter
, C Tomuleasa
, Albert Wölfler
, L Teichmann
, L Ocroteala
, K Maria-Theresa
, C Charu
, S Schlager
, V Empson
, C Klade
, K Krejcy
, H Gisslinger
, S Koschmieder

Division of Haematology

Research output: Contribution to journal › Conference abstract

Original language	English
Journal	Blood
DOIs	https://doi.org/10.1182/blood-2025-2032
Publication status	Published - 2025
Event	67th Annual Meeting of the American-Society-of-Hematology (ASH) - Orlando, United States Duration: 6 Dec 2025 → 9 Dec 2025

Branches of science

301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

DOI

10.1182/blood-2025-2032

Links

Web of Science

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera
Buxhofer-Ausch, V. (Author), Reiter, A. (Author), Tomuleasa, C. (Author), Wölfler, A. (Author), Teichmann, L. (Author), Ocroteala, L. (Author), Maria-Theresa, K. (Author), Charu, C. (Author), Schlager, S. (Author), Empson, V. (Author), Klade, C. (Author), Krejcy, K. (Author), Gisslinger, H. (Author) & Koschmieder, S. (Author)
2025
Activity: Talk, presentation or poster › Poster

Cite this

Buxhofer-Ausch, V., Reiter, A., Tomuleasa, C., Wölfler, A., Teichmann, L., Ocroteala, L., Maria-Theresa, K., Charu, C., Schlager, S., Empson, V., Klade, C., Krejcy, K., Gisslinger, H., & Koschmieder, S. (2025). Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera. Blood. https://doi.org/10.1182/blood-2025-2032

@article{98c673021a1243df95e91da881a29af3,

title = "Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera",

author = "V Buxhofer-Ausch and A Reiter and C Tomuleasa and Albert W{\"o}lfler and L Teichmann and L Ocroteala and K Maria-Theresa and C Charu and S Schlager and V Empson and C Klade and K Krejcy and H Gisslinger and S Koschmieder",

year = "2025",

doi = "10.1182/blood-2025-2032",

language = "English",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

note = "67th Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 06-12-2025 Through 09-12-2025",

}

Buxhofer-Ausch, V, Reiter, A, Tomuleasa, C, Wölfler, A, Teichmann, L, Ocroteala, L, Maria-Theresa, K, Charu, C, Schlager, S, Empson, V, Klade, C, Krejcy, K, Gisslinger, H & Koschmieder, S 2025, 'Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera', Blood. https://doi.org/10.1182/blood-2025-2032

TY - JOUR

T1 - Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

AU - Buxhofer-Ausch, V

AU - Reiter, A

AU - Tomuleasa, C

AU - Wölfler, Albert

AU - Teichmann, L

AU - Ocroteala, L

AU - Maria-Theresa, K

AU - Charu, C

AU - Schlager, S

AU - Empson, V

AU - Klade, C

AU - Krejcy, K

AU - Gisslinger, H

AU - Koschmieder, S

PY - 2025

Y1 - 2025

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:1660219100032

U2 - 10.1182/blood-2025-2032

DO - 10.1182/blood-2025-2032

M3 - Conference abstract

SN - 0006-4971

JO - Blood

JF - Blood

T2 - 67th Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 6 December 2025 through 9 December 2025

ER -

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

Branches of science

DOI

Links

Activities

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

Cite this